Pharmakologie von Prokinetika

Hellenbrecht, D.

doi:10.1007/978-3-642-76148-5_1

Cited by 2 publications

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacological treatment for functional dyspepsia includes synthetic gastroprokinetics which primarily aim at increasing the motility function (e.g. metoclopramide, domperidone, cisapride), but also angiotensin and antagonists of gastrointestinal hormones, acid‐reducing drugs, or bismuth preparations 2 . Additionally, phytomedical drugs, which often show a broader pharmacological spectrum and better tolerability than synthetic drugs, have a long tradition in the treatment of functional gastrointestinal diseases 3 –5 …”

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia

May¹,

Köhler

Schneider

2000

Aliment Pharmacol Ther

175

View full text Add to dashboard Cite

Aim: To assess the efficacy and safety of enteric coated capsules containing a fixed combination of 90 mg peppermint oil and 50 mg caraway oil (PCC; Enteroplant) in patients with functional dyspepsia. Methods: A total of 96 out‐patients received one capsule twice daily of PCC or placebo for 28 days. Primary efficacy variables were the intra‐individual change in (i) pain intensity and (ii) sensation of pressure, heaviness and fullness between days 1 and 29, and the investigators’ rating of (iii) global improvement (Clinical Global Impressions [CGI] item 2) on day 29. A global type I error of α=0.05 was controlled by a priori ordering of hypotheses. Results: All patients were evaluable for efficacy and safety. On day 29, the average intensity of pain was reduced by 40% vs. baseline in the PCC group and by 22% in the placebo group. With regards to pressure, heaviness and fullness, a 43% reduction was observed for PCC vs. 22% for placebo. In CGI item 2, 67% (PCC) vs. 21% (placebo) of the patients were described as much or very much improved. In all three target parameters, the superiority of PCC over placebo was statistically significant. Six patients (PCC: 5; placebo: 1) reported adverse events, either unrelated to the trial, or attributable to an aggravation of the disease under investigation. Eructation with peppermint taste did not occur. Conclusion: These results demonstrate the good tolerability and the favourable risk–benefit ratio of PCC for the treatment of functional dyspepsia.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia

May¹,

Köhler

Schneider

2000

Aliment Pharmacol Ther

175

View full text Add to dashboard Cite

show abstract

Medical treatment of esophageal motility disorders

Allescher

Ravich

1993

Dysphagia

View full text Add to dashboard Cite

Swallowing is a complex mechanism that is based on the coordinated interplay of tongue, pharynx, and esophagus. Disturbances of this interplay or disorders of one or several of these components lead to dysphagia, non-cardiac chest pain, or regurgitation. The major esophageal motility disorders include achalasia, diffuse esophageal spasm, hypercontractile esophagus ("nutcracker esophagus"), and hypocontractile esophagus ("scleroderma esophagus"). Other esophageal diseases such as hypopharyngeal (Zenker's) diverticula or gastroesophageal reflux disease also may be sequelae of primary esophageal motility disorder. Finally, a substantial group of patients referred for evaluation of possible esophageal motor disorders have milder degrees of dysmotility--referred to as nonspecific esophageal motor disorder--that are of unclear clinical significance. Medical treatment of esophageal motility disorders involves the uses of agents that either reduce (anti-cholinergic agents, nitrates, calcium antagonists) or enhance (prokinetic agents) esophageal contractility. Despite the beneficial effect of the various drugs on esophageal motility parameters, the clinical benefit of medical treatment is often disappointing. From clinical and epidemiological studies there is some evidence for a "psychological" component in the pathogenesis or perception of esophageal symptoms. Further understanding of esophageal pathophysiology, as well as development of new receptor selective drugs, might increase our chances of successful treatment of esophageal motility disorders.

show abstract

Pharmakologie von Prokinetika

Cited by 2 publications

References 85 publications

Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia

Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia

Medical treatment of esophageal motility disorders

Contact Info

Product

Resources

About